Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaunoXome vs Daunorubicin in Elderly AML
NCT00589082Phase 3Completed
- Sponsor
- GIMEMA
- Start
- Oct 2001
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of daunorubicin in acute myeloid leukemia (AML), sponsored by GIMEMA. Started Oct 2001; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00589082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589082.